Our results showed that CKI combined with chemo can significantly increase CD3+ and CD4+/CD8+ compared with chemo alone, suggesting that CKI can improve the chemotherapy-induced immunosuppression by regulating the expression of T lymphocyte subsets, thereby enhancing the immune function of patients with NSCLC. The gene discussed is CD4; the disease is non-small cell lung carcinoma.